indenolol

RN given refers to parent cpd without isomeric designation; structure

Also Known As:

1-(7-indenyloxy)-3-isopropylaminopropan-2-ol.HCl; YB-2; indenolol hydrochloride; indenolol, HCl(+)-isomer; indenolol, HCl(+-)-isomer; indenolol, HCl(R)-isomer; indenolol, HCl(S)-isomer; 1-(1H-inden-7-yloxy)-3-((1-methylethyl)amino)-2-propanol, hydrochloride

Networked: 26 relevant articles (1 outcomes, 3 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Asao, Takayuki: 2 articles (06/2007 - 09/2002)
2.	Ide, Munenori: 2 articles (06/2007 - 09/2002)
3.	Saniabadi, Abby R: 2 articles (06/2007 - 09/2002)
4.	Yazawa, Shin: 2 articles (06/2007 - 09/2002)
5.	Hashimoto, Shinji: 1 article (06/2007)
6.	Kominato, Yoshihiko: 1 article (06/2007)
7.	Kuwano, Hiroyuki: 1 article (06/2007)
8.	Noguchi, Kasumi: 1 article (06/2007)
9.	Tsuboi, Kaori: 1 article (06/2007)
10.	Kochibe, Naohisa: 1 article (09/2002)

Related Diseases

1.	Essential Hypertension 01/01/1985 - "We conclude that indenolol exerted a marked effect on chronotropism but no demonstrable negative effect on inotropism in patients with essential hypertension. " 01/01/1985 - "The effect of indenolol on heart rate and blood pressure at rest and after submaximal workload has been studied in 19 patients with established essential hypertension. " 01/01/1985 - "Haemodynamic effects of indenolol at rest and after a submaximal workload in essential hypertension." 11/01/1984 - "For clarifying the onset mechanism of essential hypertension, the hemodynamics in 9 mildly hypertensive men, mean age of 39.8 +/- 10.7 (mean +/- SD), was compared with 7 normotensive men, mean age of 39.8 +/- 10.7, by means of exercise echocardiography, and the effects of indenolol (administered 30 mg/day for 7 days orally to both groups) were studied. " 12/01/1986 - "The aim of this study was to evaluate BAR density and affinity before and after indenolol therapy in membranes of polymorphonucleates (PMN) of patients with essential hypertension. "
2.	Hypertrophy 11/01/1990 - "Indenolol caused a regression of LV hypertensive hypertrophy without impairment of LV systolic function." 11/01/1990 - "This study evaluated the effect of long-term antihypertensive therapy with indenolol, a beta blocking agent with beta 2 stimulating activity, its antihypertensive hemodynamic mechanism and its effect on hypertensive left ventricular (LV) hypertrophy. "
3.	Hypertension (High Blood Pressure) 11/01/1990 - "[Effects of indenolol on left ventricular mass in patients with essential arterial hypertension]." 09/01/1986 - "Indenolol kinetics versus pharmacodynamics in hypertension." 07/01/1985 - "The relationship between indenolol (an investigational agent) plasma levels and the drug's effect on blood pressure and heart rate was investigated after single and repeated once daily administration at two dosage levels (60 mg and 120 mg) in two different groups of patients with first or second stage hypertension, according to the World Health Organization classification. " 11/01/1984 - "The hemodynamics and hemodynamic effects of indenolol in mild hypertension." 03/01/1983 - "The effect of indenolol on systolic arterial pressure was dose and time related, but independent of the intensity of hypertension. "
4.	Colorectal Neoplasms (Colorectal Cancer) 06/01/1993 - "Therefore, YB-2 antibody could be useful as an immunochemical tool for diagnosis and evaluation of the prognosis of colorectal cancer." 09/01/2002 - "The accumulation of alpha1,2fucosylated antigens, such as Y (Fucalpha1,2Galbeta1,4 [Fucalpha1,3]GlcNAcbeta), Le(b) (Fucalpha1,2Galbeta1,3-[Fucalpha1,4]GlcNAcbeta), and H type 2 (Fucalpha1,2 Galbeta1,4GlcNAcbeta) occurs specifically within human colorectal tumor tissues and can be detected by an antifucosylated antigen antibody, such as the YB-2 antibody. " 06/01/1993 - "The expression of fucosylated antigens detected by YB-2 antibody seemed to be correlated with survival among patients with primary colorectal cancer. " 01/01/1994 - "Of 64 colorectal cancers, 59 (92.2%) were stained by the YB-2 antibody; however, only 3 (12.0%) of 25 samples of normal colon mucosa and 13 (50.0%) of 26 adenomas expressed the antigens recognized by YB-2. " 06/01/2007 - "By using the YB-2 monoclonal antibody, the resulting products have been identified as Y, Le(b), and H type 2 antigens in colorectal tumor tissues. "
5.	Tachycardia (Tachyarrhythmias) 04/01/1981 - "Dose-response curves for both drugs revealed that maximum attenuation of exercise tachycardia and systolic blood pressure were in the same range but suggested that indenolol induced a greater response in the lower doses. " 04/01/1981 - "Indenolol induced attenuation of exercise-induced rise in systolic blood pressure and tachycardia. " 02/01/1986 - "In conscious SHRs the acute hypotensive effect of oral indenolol and pindolol was associated with marked bradycardia and moderate tachycardia respectively, while the decrease in heart rate following propranolol was concomitant to a slight increase in blood pressure. "

Related Drugs and Biologics

1.	Antihypertensive Agents (Antihypertensives)
2.	Antigens
3.	Propranolol (Inderal)
4.	Monoclonal Antibodies
5.	Metoprolol (Toprol-XL)
6.	Glycosyltransferases
7.	Thyroid Hormones
8.	Sucralfate (Carafate)
9.	Solutions
10.	beta Adrenergic Receptors

Related Therapies and Procedures

1.	Therapeutics
2.	Intravenous Administration
3.	Oral Administration